



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2013

Cyclosporine for the treatment of feline allergic skin diseases

Favrot, C

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-87435>

Conference or Workshop Item

Originally published at:

Favrot, C (2013). Cyclosporine for the treatment of feline allergic skin diseases. In: ESVD-ECVD Annual Meeting, Valencia, Spain, 19 September 2013 - 21 September 2013.

Cyclosporine therapy for feline hypersensitivity dermatitis

Claude Favrot

**Dermatology Service, Vetsuisse Faculty, University of Zurich, Zurich,
Switzerland**

Cyclosporine A (CsA) is an immunomodulatory drug belonging to the group of calcineurin inhibitors. This lipophilic drug penetrates easily the cell membranes and binds in the cytoplasm to cyclophilin. CsA-Cyclophilin complex inhibits calcineurin, leading to an impaired activation of Nuclear Factor of Activated T cells (NF-AT). As NF-AT is one of the major activator of cytokine genes transcription, CsA administration results in an impaired expression of cytokines.

At the cellular level, CsA inhibits T lymphocyte activation, eosinophil recruitment, functions and growth of antigen-presenting cells, especially Langerhans cells, pro inflammatory cytokines secretion of keratinocytes and IgE mediated mast cell degranulation.

After oral or intravenous administration, peak and trough levels are highly variable in cats. It has however been shown that serum concentration and clinical efficacy are not correlated which implies that routine evaluation of CsA blood concentration is not necessary, in most occasions. The peak concentration is obtained one hour after oral administration of 5mg/kg CsA and ranges between 100 and 1600 ng/ml when measured by high-pressure liquid chromatography. It is worth noticing that CsA values depend on the technique used and immunoassays provided usually much higher values, when compared with high pressure chromatography.

The bioavailability of CsA in cats is rather low (29%) and bioaccumulation is usually not observed. As mentioned above, CsA is a very lipophilic drug, which explains the high volume of distribution (6L/kg) as well as the high concentration in the skin (4 times higher than in serum). Feeding before CsA administration is associated with a lower bioavailability but this decrease does not seem to impair clinical outcomes.

CsA interacts with cytochrome P 450 3A4 and drug interactions are consequently numerous. Very few have however been demonstrated in clinical study and these interactions may be influenced by several factors such as age, concurrent diseases, dosage etc... In cats, interaction between CsA and ketoconazole, itraconazole and clarithromycin have been demonstrated. Concomitant treatment should be associated with a reduction of CsA administration. Other possible interaction with ranitidine, omeprazole, cimetidine, metoclopramide, allopurinol, erythromycin, digoxin, furosemide, ciprofloxacin, verapamil and trimethoprim-sulfa are likely.

Side-effects of CsA include gastrointestinal signs, anorexia, weight loss and gingivitis. Otitis and cystitis are also sometimes observed during CsA treatment even though causality is not firmly established^{1,2}. Outdoor cats should also be tested for

toxoplasma IgG before treatment and negative cats should not be treated or should be kept indoors during the whole treatment. On the contrary, IgG positive cats are protected. As well, cats with chronic infectious diseases such as FIV, FeLV, dermatophytosis should not be treated with CsA. Cats with chronic kidney deficiency and diabetes mellitus could be treated with CsA but should be monitored carefully.

In a Novartis intern study (freedom of information), cats were first vaccinated and, then, treated 4 months afterwards with CsA 24mg/kg during 8 weeks. These cats were subsequently re-vaccinated after this period of treatment: Titers were lower than in the control group but still in normal range which suggests that booster vaccination could be made during CsA treatment.

The first evidence for the efficacy of CsA for the treatment of hypersensitivity cats was provided by an open study published by Noli and coworkers³. The first controlled study was published by Wisselink and coworkers who compared two groups of allergic cats, the first one being treated with CSA 5 mg/kg and the second one with Prednisolone 0.5mg/kg. Improvement of the clinical signs were seen in both groups⁴. Larger studies were published afterwards and evidence was provided that the better dosage for allergic cats was 7 mg/kg². Some other studies were carried out afterwards but are still not published. It was however demonstrated that after an initial phase of treatment of 6 to 8 weeks, about 70% of allergic cats only need every other day treatment. After 4 additional weeks, 55 % were treated only twice a week while 20 % were still on every other day treatment and 15% on daily administration. Only 10% did not respond to the treatment.

All in all, studies show that CsA is a good treatment option for allergic cats and that most of them support the treatment well.

References

1. Heinrich NA, McKeever PJ, Eisenschenk MC. Adverse events in 50 cats with allergic dermatitis receiving ciclosporin. *Veterinary Dermatology*. 2011;22:511-520.
2. King S, Favrot C, Messinger L et al. A randomised double-blinded placebo controlled study to evaluate an effective ciclosporin dose for the treatment of feline hypersensitivity dermatitis. *Veterinary Dermatology*. 2012;In press.
3. Noli C, Scarpella F. Prospective open pilot study on the use of ciclosporine for feline allergic skin disease. *Journal of Small Animal Practice*. 2006;47:434-438.
4. Wisselink MA, Willemse T. The efficacy of cyclosporine A in cats with presumed atopic dermatitis: A double blind, randomised prednisolone-controlled study. *The Veterinary Journal*. 2009;180:55-59.